Navigation Links
Halozyme Announces Proposed Public Offering of Common Stock
Date:2/9/2012

documents that Halozyme has filed, or will file, with the SEC for more complete information about Halozyme and this offering. You may access these documents, when available, free of charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the public offering) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
2. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
3. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
4. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
5. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
6. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
7. Halozyme Therapeutics to Present at Upcoming Financial Conferences
8. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
9. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
10. Halozyme and Intrexon Announce Collaboration to Develop First Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
11. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LAKE FOREST, Ill. , Dec. 19, 2014 /PRNewswire/ ... the world,s leading provider of injectable drugs and infusion ... the J.P. Morgan 33rd Annual Healthcare Conference on Wednesday, ... The presentation is scheduled to begin at 10:30 ... will be available to all interested parties through a ...
(Date:12/19/2014)... Dec. 19, 2014 In today,s rapidly ... marketing communication tools are essential for survival. The ... consequently consumers, desires, preferences, and unmet needs are ... research groups across all industries are continually searching ... However, the adoption of new market research techniques ...
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , Dec. ... SRNE ;  Sorrento), an oncology company developing ... Conkwest, Inc., a privately-held immuno-oncology company developing proprietary ... cell-line based therapy, announced today that the companies ... develop next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5
... for Treating Motor System Disorders, LA JOLLA, ... currently in clinical development by TorreyPines Therapeutics,Inc. (Nasdaq: ... migraine headache, was shown,in an independent study to ... rigidity in a rat model of spinal ischemia. ...
... Pharmion Corporation,(Nasdaq: PHRM ) today announced ... trial evaluating amrubicin, the Company,s third-generation,synthetic anthracycline, in ... The randomized, controlled, multi-center study will compare,amrubicin to ... SCLC in the US and EU. Enrollment in ...
Cached Medicine Technology:Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego 2Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego 3Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego 4Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer 2Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer 3Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer 4Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer 5
(Date:12/19/2014)... 19, 2014 Silver Dollar City ... record -- for the first time ever, Silver Dollar City ... Guinness World Records 2015, listing the park’s wood coaster Outlaw ... In additional awards announced this week, Silver Dollar City is ... in the US,” USA Today’s 10Best awards for “Best Public ...
(Date:12/19/2014)... 20, 2014 These vanadium reserves are ... nations. Around 151,000 tons of vanadium were produced globally ... vanadium usage increased at 6.7% AAGR during the period ... iron industry, being the largest consumer, accounted for more ... by titanium-vanadium alloy and the chemical industry. , View ...
(Date:12/19/2014)... The print component of Vision and ... of the Toronto Star, with a circulation of approximately ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... publication features an exclusive interview with Mark DeMontis ...
(Date:12/19/2014)... (HealthDay News) -- All children should have their eyesight ... every year, eye experts say. The new vision-screening ... of the U.S. National Center for Children,s Vision Health. ... group require screening for eye problems, particularly vision ... ("lazy eye") and strabismus (a disorder of eye alignment). ...
(Date:12/19/2014)... -- Dense bunches of bacteria called biofilms can be found ... The researchers said these biofilms were especially prevalent ... of these biofilms may represent an increased likelihood of colon ... person,s risk for the disease, the researchers said. Like ... coat the mucus layer of cells lining the colon, according ...
Breaking Medicine News(10 mins):Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Could Bacteria Play a Role in Colon Cancer? 2
... bald mice to get fur on the body, says a ... C. Thompson and colleagues at Johns Hopkins University School// of ... encodes a protein that is essential for hair follicle regeneration. ... Hairless gene, hair growth is initially normal. But once hair ...
... but that is the place no one looks. Same is ... control protein with a key role in the brain's ability ... treating obesity and type 2 diabetes. ,The findings in ... might underlie obesity in humans, the researchers said. SH2-B, which ...
... temporarily ban the Environmental Protection Agency (EPA) from using ... marketed//. Lawmakers on Capitol Hill will soon decide whether ... and use of studies that expose participants to pesticides. ... to have their pesticides approved by the agency for ...
... living with HIV/AIDS in Manipur have hope at hand ... specialised clinics for their care and treatment//.,The Nobel prize-winning ... signed a memorandum of understanding with the Manipur government ... HIV/AIDS. ,The Dutch chapter of the MSF ...
... make some people vulnerable to suffer from the dreaded ... can diagnose the risk//. ,According to the most ... by the researchers from Vanderbilt University in Nashville, Tennessee ... Association in San Diego, a cluster of genes on ...
... help of carotid endarterectomy, said a report in the ... is the most frequently performed operation to prevent stroke//. ... prevent future stroke, according to a clinical practice guideline ... Neurology (AAN). The guideline updates the 1990 AAN statement ...
Cached Medicine News:Health News:An Answer To Obesity: Weight Control Protein 2Health News:US Senate Votes against Testing of Pesticide on Humans 2Health News:Specialized Clinics For Manipur's AIDS Patients 2Health News:Carotid Endarterectomy Beneficial for Stroke Prevention 2
... segment surgeries Vitrectomy-Lensectomy + Irrigation/Aspiration system ... Linear Aspiration. Interchangeable disposable blades can ... Easy to read LED display for ... 1- 600 cuts per minute. Independent ...
Mendez Multi-Purpose LASIK Forceps. To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps, Titanium...
Hockey Knife For PRK - Also available in Titanium...
The CGAL gonioscopic contact glass was designed by Roussel and Fankhauser for,laser treatments of the chamber angle. It reduces the laser spot by a factor of 1.5 as compared to a Goldmann Glass....
Medicine Products: